Iradimed Corp (IRMD)
NASDAQ:IRMD
Want to see IRMD full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.45Last Year’s EPS
0.49Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong Q1 financial results (13% revenue growth, 33% operating income growth, double-digit net income improvement), healthy margins, substantial cash generation, and an encouraging early 3870 product launch with higher-than-expected ASP and quad-system demand. Near-term headwinds are primarily transitional and execution-related: a planned conservative manufacturing ramp (130–135 3870s in Q2) leads to guidance showing a modest Q2 revenue dip versus Q1, and there are temporary tax and R&D expense effects. These lowlights appear manageable relative to the magnitude of the reported financial improvements and the sizeable replacement opportunity for the 3870, so positive momentum is the dominant theme.Company Guidance
Revenue Growth
Q1 2026 revenue of $22.0M, up 13% year-over-year versus $19.5M in Q1 2025.
Improved Profitability
Operating income of $7.2M, a 33% increase YoY; GAAP net income of $5.8M, up 22% YoY; GAAP diluted EPS of $0.45. Non-GAAP net income of $6.4M, or $0.49 per diluted share, up 17%.
Strong Segment Performance
IV infusion pump systems revenue $7.7M, up 28% YoY (backlog fulfillment); patient monitoring revenue $7.1M, up 9% YoY; disposables $4.9M (flat YoY); Ferro-magnetic Detection Systems contributed $0.6M.
Healthy Margins and Cash Generation
Gross profit $16.8M with gross margin of 77% (up from 76% a year ago). Cash and cash equivalents $56.4M. Operating cash flow $8.3M, up 93% YoY; non-GAAP free cash flow $7.8M after ~$0.5M capex.
Very Promising 3870 Product Launch
Initial quoting/orders for the new 3870 MRI IV pump show ASP lift closer to ~20% (vs prior expectation of 10–14%). Majority of early orders are quad (4-channel) systems, increasing per-order ASP and channel count; orders and dollar size are well ahead of early expectations.
Clear Runway and Financial Targets
Company reaffirmed full-year 2026 guidance: revenue $91–96M, GAAP diluted EPS $1.90–2.05, non-GAAP diluted EPS $2.06–2.21. Board declared quarterly cash dividend of $0.20 per share. Management projects domestic pump run rate north of 2,000 channels and a potential ~$50M pump revenue run rate, with a company target of $100M+ revenue run rate as 3870 ramps and add-on revenue (disposables, maintenance, monitoring, international) grows.
IRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2026 | $83.44 | $87.15 | +4.45% |
Feb 10, 2026 | $95.78 | $104.95 | +9.57% |
Nov 03, 2025 | $76.11 | $83.35 | +9.50% |
Aug 01, 2025 | $57.67 | $65.41 | +13.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iradimed Corp (IRMD) report earnings?
Iradimed Corp (IRMD) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Iradimed Corp (IRMD) earnings time?
Iradimed Corp (IRMD) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRMD EPS forecast?
IRMD EPS forecast for the fiscal quarter 2026 (Q2) is 0.45.